Impact of media coverage on side effect reports from the COVID-19 vaccine.
Anxiety
COVID-19
Media
Nocebo effect
Vaccination
Journal
Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
received:
21
05
2022
revised:
10
11
2022
accepted:
12
11
2022
pubmed:
27
11
2022
medline:
13
1
2023
entrez:
26
11
2022
Statut:
ppublish
Résumé
Past research shows that media coverage of medicine side effects can produce a nocebo response. New Zealand news media discussed myocarditis following the Pfizer COVID-19 vaccine. This study examined whether side effects mentioned in the media increased compared to control symptoms not mentioned. The study analysed 64,086 vaccine adverse reaction reports, retrieved from the medicine safety authority. Generalised linear regressions compared the side effect rate during three discrete periods of media reporting (August 2021, December 2021, April 2022) with the pre-media baseline rate. The outcomes were weekly reports of chest discomfort, monthly reports of chest, heart and breathing symptoms, and myocarditis, pericarditis, and anxiety. Control symptoms were fever, numbness, and musculoskeletal pain. Logistic regressions investigated factors associated with side effect reporting. The reporting rate of chest discomfort was 190% greater in the five weeks after the first media item (p < .001). The monthly reporting rates of the symptoms mentioned in the media were significantly greater after the news coverage (ps ≤ 0.001). There was no effect of media on the control side effect fever (p = .06). There was an effect of media on myocarditis, pericarditis and anxiety (ps < 0.001). Anxiety, male gender, and younger age were significantly associated with side effects. The results indicate that a media-induced nocebo response occurred. This is most likely due to increased expectations and awareness of COVID-19 vaccine side effects, elevated symptom experience from anxiety, and consequently greater reporting of the symptoms in line with the media coverage.
Identifiants
pubmed: 36435094
pii: S0022-3999(22)00378-6
doi: 10.1016/j.jpsychores.2022.111093
pmc: PMC9670676
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111093Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.